文章：

意义未明的单克隆丙种球蛋白病与COVID-19：一项基于人群的队列研究

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

原文发布日期：2021-12-01

DOI: 10.1038/s41408-021-00580-7

类型: Article

开放获取: 是

英文摘要：

Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81–1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.
 

摘要翻译： 

多发性骨髓瘤患者感染严重急性呼吸综合征冠状病毒2型后，罹患2019冠状病毒病的重症风险较高。意义未明的单克隆丙种球蛋白病作为多发性骨髓瘤的前期病变，与可能导致重症COVID-19的免疫功能紊乱相关。目前尚未有关于MGUS患者COVID-19情况的系统性数据发表。我们开展了一项大规模人群队列研究，评估MGUS个体感染SARS-CoV-2及发展为重症COVID-19的风险。研究纳入75,422名1976年前出生的冰岛居民，这些参与者均在"冰岛多发性骨髓瘤筛查、治疗与预防研究"中接受过MGUS筛查。SARS-CoV-2检测数据与COVID-19严重程度信息来自冰岛COVID-19研究组。采用检测阴性研究设计，我们纳入32,047名接受过SARS-CoV-2检测的iStopMM参与者，其中1754人患有MGUS。在这些参与者中，1100人检测结果呈阳性（含65例MGUS患者），230人发展为重症COVID-19（含16例MGUS患者）。MGUS与SARS-CoV-2感染风险（比值比：1.05；95%置信区间：0.81–1.36；p=0.72）或重症COVID-19（比值比：0.99；95%置信区间：0.52–1.91；p=0.99）均无显著关联。这些研究结果表明，MGUS不影响个体对SARS-CoV-2的易感性或COVID-19的严重程度。

原文链接：

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study